Home › Funds › Trails Edge Capital Partners, LP › FDMT

Trails Edge Capital Partners, LP position in FDMT

4D MOLECULAR THERAPEUTICS IN · Health Care

Trails Edge Capital Partners, LP reported holding 2,227,917 shares of FDMT (4D MOLECULAR THERAPEUTICS IN) in its Q2 2026 13F filing — a position valued at US$29.6M, representing 4.70% of its reported portfolio and ranking #5 among its reported holdings. Trails Edge Capital Partners, LP has disclosed FDMT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)2.23M sh
Reported value held$29.63M
Portfolio Weight4.70%
First reportedQ1 2026
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Trails Edge Capital Partners, LP's FDMT position evolved

Trails Edge Capital Partners, LP first disclosed a stake in FDMT in Q1 2026 at 1,302,917 shares (US$12.1M). The position peaked in Q2 2026 at 2,227,917 shares, worth US$29.6M. Across 2 filings, Trails Edge Capital Partners, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,227,917 shares valued at US$29.6M — an increase of 925,000 shares quarter over quarter.. Notable position changes include a 71% increase in Q2 2026 (shares rose 8% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 1.30M $12.13M New
Q2 2026 2.23M $29.63M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About FDMT and 13F data

FDMT (4D MOLECULAR THERAPEUTICS IN) is a Health Care company. 35 other funds we track also report a position in FDMT — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$67.2M), Novo Holdings A/S (US$43.2M), BVF INC/IL (US$38.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding FDMT

All FDMT fund holders →

FAQ

How long has Trails Edge Capital Partners, LP held FDMT?

Trails Edge Capital Partners, LP has disclosed FDMT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is Trails Edge Capital Partners, LP's current position in FDMT?

As of Q2 2026, Trails Edge Capital Partners, LP holds 2.23M shares of FDMT (4D MOLECULAR THERAPEUTICS IN), valued at $29.63M, representing 4.70% of its reported portfolio and ranking #5.

Has Trails Edge Capital Partners, LP been buying or selling FDMT?

In the latest 13F filing (Q2 2026), Trails Edge Capital Partners, LP increased its position in FDMT. The position peaked in Q2 2026 at 2.23M shares.

Which other funds hold FDMT?

Other major institutional holders of FDMT include RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, BVF INC/IL, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.